Evidence map›Paper›PMID 23131503›Full record

ArticleCardiovascular research2013

α-Melanocyte-stimulating hormone regulates vascular NO availability and protects against endothelial dysfunction.

Petteri Rinne, Wendy Nordlund, Ilkka Heinonen, Anna-Maija Penttinen, Antti Saraste, Suvi T Ruohonen, Satu Mäkelä, Laura Vähätalo, Katja Kaipio, Minying Cai and 3 more

Abstract read
In one paragraph

Article in Cardiovascular research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Petteri RinneDepartment of Pharmacology, Drug Development and Pharmaceutics, and Turku Center for Disease Modeling, Itäinen Pitkäkatu 4b, 20014 University of Turku, Turku, Finland. pperin@utu.fi
Wendy Nordlund
Ilkka Heinonen
Anna-Maija Penttinen
Antti Saraste
Suvi T Ruohonen
Satu Mäkelä
Laura Vähätalo
Katja Kaipio
Minying Cai
Victor J Hruby
Saku Ruohonen
Eriika Savontaus

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsα-Melanocyte-stimulating hormone (α-MSH), derived from the precursor molecule pro-opiomelanocortin, exerts potent anti-inflammatory actions in the vasculature, but its role in circulatory regulation remains unclear. Therefore, we sought to investigate whether α-MSH could regulate the local control of blood vessel tone. METHODS AND

resultsUsing in vivo and ex vivo methods to assess vascular reactivity, we found that α-MSH improved endothelium-dependent vasodilatation in the mouse aorta and coronary circulation without directly contracting or relaxing blood vessels. α-MSH promoted vasodilatation by enhancing endothelial nitric oxide (NO) formation and by improving sensitivity to endothelium-independent blood vessel relaxation. Using cultured human endothelial cells to elucidate the involved molecular mechanisms, we show that α-MSH increased the expression and phosphorylation of endothelial NO synthase in these cells. The observed effects were regulated by melanocortin 1 (MC1) receptors expressed in the endothelium. In keeping with the vascular protective role of α-MSH, in vivo treatment with stable analogues of α-MSH ameliorated endothelial dysfunction associated with aging and diet-induced obesity in mice.

conclusionThe present study identifies α-MSH and endothelial MC1 receptors as a new signalling pathway contributing to the regulation of NO availability and vascular function. These findings suggest applicability of α-MSH analogues for therapeutic use in pathological conditions that are characterized by vascular dysfunction.

Indexed as

Acetylcholinealpha-MSHAnimalsCells, CulturedCoronary CirculationEndothelium, VascularHumansMiceMice, Inbred C57BLNitric OxideNitric Oxide Synthase Type IIIReceptor, Melanocortin, Type 1Signal TransductionVasodilationAcetylcholinealpha-MSHNitric OxideNitric Oxide Synthase Type IIIReceptor, Melanocortin, Type 1

Identifiers

PMID23131503
PMCPMC3543993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.